Mode
Text Size
Log in / Sign up

Machine learning model predicts functional status in patients with traumatic brain injury, intracerebral hemorrhage, or aneurysmal subarachnoid hemorrhage

Machine learning model predicts functional status in patients with traumatic brain injury, intracere…
Photo by Ryunosuke Kikuno / Unsplash
Key Takeaway
Note that a machine learning model integrating liver markers predicted functional status in neurosurgical patients with an AUC of 0.932.

This retrospective cohort study focused on patients with traumatic brain injury, intracerebral hemorrhage, or aneurysmal subarachnoid hemorrhage. The sample size and setting were not reported. The study aimed to develop a machine learning model using liver function markers and other features to predict functional status at discharge, assessed via the modified Rankin Scale.

The primary model performance results for the CatBoost algorithm showed an AUC of 0.932, accuracy of 0.879, precision of 0.872, recall of 0.810, F1 score of 0.840, and Brier score of 0.116. Predictive features included lower GCS score at admission and older age, which predicted unfavorable outcomes. Higher mean AST, mean ALKP, and initial ALKP were associated with unfavorable outcomes, as were lower mean and minimum albumin levels.

Safety data, adverse events, and discontinuations were not reported. The study describes associations between liver function markers and outcomes rather than causality. Future studies are needed for external validation through multicenter investigations. The need to explore mechanistic associations between liver dysfunction and neurological deterioration was identified as a key limitation.

The practice relevance indicates that the machine learning model showed excellent performance in predicting the prognosis of neurosurgical patients by integrating neurological and liver function markers. However, the model performance in external settings remains uncertain until further validation occurs.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
IntroductionEarly prediction of prognosis for neurosurgical diseases remains challenging. This study aimed to develop a machine learning-based model to predict unfavorable outcomes in neurosurgical patients.MethodsWe conducted a retrospective cohort study of patients with traumatic brain injury, intracerebral hemorrhage, or aneurysmal subarachnoid hemorrhage between 2018 and 2020. The primary outcome was functional status at discharge, assessed via the modified Rankin Scale. Feature selection used LASSO regression and the Boruta algorithm, with overlapping selected features retained for model development. Six machine learning algorithms were trained with 5-fold cross-validation for hyperparameter optimization via Optuna. Model performance was evaluated using area under the receiver operating characteristic curve (AUC), calibration curves, and decision curve analysis. Shapley additive explanations were used for interpretability.ResultsThe CatBoost model performed best (AUC = 0.932, accuracy = 0.879, precision = 0.872, recall = 0.810, F1 score = 0.840, Brier score = 0.116), balancing discriminative power and clinical relevance. Key predictive features included Glasgow Coma Scale (GCS) score at admission, age, and liver function markers including aspartate transaminase (AST) mean, albumin mean, alkaline phosphatase (ALKP) mean, ALKP max, albumin min, and ALKP first. Lower GCS score at admission and older age predicted unfavorable outcomes. Higher mean AST, mean ALKP and initial ALKP, as well as lower mean and minimum albumin, were associated with unfavorable outcomes.DiscussionThe CatBoost model showed excellent performance in predicting the prognosis of neurosurgical patients by integrating neurological and liver function markers. Future studies are needed for external validation through multicenter investigations, and explore mechanistic associations between liver dysfunction and neurological deterioration.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.